Dose-Timing Intervals of Antiretroviral Medications and Virologic Responses

• Activity Number: 489
• Type: Invited
• Date/Time: Thursday, August 2, 2007 : 8:30 AM to 10:20 AM
• Sponsor: ENAR
• Author(s): Honghu Liu*+ and Loren G. Miller and Ron D. Hayes and Carol E. Golin and Junfeng Sun and Tongtong Wu and Neil S. Wenger
• Companies: University of California, Los Angeles and University of California, Los Angeles and University of California, Los Angeles and The University of North Carolina at Chapel Hill and University of Nebraska Medical Center and University of California, Los Angeles and University of California, Los Angeles
• Keywords: Adherence ; Dose timing ; Genotypic sensitivity ; Viral load ; HIV/AIDS

Abstract

Adherence is a main predictor of the effectiveness of antiretroviral medications in HIV treatment. But studies have focused primarily on the percent of prescribed doses taken (percent adherence). We collected detailed adherence data including dose timing and patients' virologic responses. For 48 weeks, adherence and virologic outcomes were collected every 4 weeks, and demographics and other measures were collected at baseline and weeks 8, 24, and 48. We constructed 8 dose timing error (DTE) measures and evaluated their associations with virologic outcomes. Repeated measures mixed effect models were fitted to evaluate the predicting power of these DTE measures. Among 52,036 electronically recorded doses from 122 patients, DTE measures significantly predicted virologic outcomes. Six DTE measures were significantly predictive of virologic outcomes after controlling for percent adherence.